Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Change in Accured Expenses for 7 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 83.41% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.0 million through Dec 2025, up 449.58% year-over-year, with the annual reading at $23.0 million for FY2025, 449.58% up from the prior year.
  • Change in Accured Expenses hit $19.8 million in Q4 2025 for BridgeBio Pharma, up from $18.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $19.8 million in Q4 2025 to a low of -$18.6 million in Q2 2025.
  • Historically, Change in Accured Expenses has averaged $2.1 million across 5 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 23700.0% in 2021 and later skyrocketed 441.34% in 2025.
  • Year by year, Change in Accured Expenses stood at $15.8 million in 2021, then tumbled by 57.2% to $6.8 million in 2022, then grew by 13.51% to $7.7 million in 2023, then skyrocketed by 40.77% to $10.8 million in 2024, then skyrocketed by 83.41% to $19.8 million in 2025.
  • Business Quant data shows Change in Accured Expenses for BBIO at $19.8 million in Q4 2025, $18.8 million in Q3 2025, and -$18.6 million in Q2 2025.